Back to search

Poland· PL-100250828

Aminoplasmal B. Braun 10%

A aminosäuren product containing produkt złożony, registered in Poland by B. Braun Melsungen AG. The same ATC class is registered in 11 of our 19 countries.

ATC B05BA01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAminoplasmal B. Braun 10%ATCB05BA01REGISTER NO.PL-100250828PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Aminosäuren is registered in 11 of 19 countries.

Countries holding a registration under ATC B05BA01 (aminosäuren), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Aminosäuren · ATC B05BA01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Produkt złożony
Manufacturer
B. Braun Melsungen AG
Country
Poland (PL)
ATC code
B05BA01
ATC class
Aminosäuren
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991203634
  • gtin
    05909991203641
  • gtin
    05909991203658

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

4 interactions on record for aminosäuren.

Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Aminosäuren · interactions on record

4 records

  • 4 moderate

Most severe, free to view

  • AmfetamineN06BA01moderate
  • DexamfetamineN06BA02moderate
  • MetamfetamineN06BA03moderate
  • LisdexamfetamineN06BA12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/48042f48-e71c-47c5-a1d8-4a605f4e62f1
GET /v1/drugs/48042f48-e71c-47c5-a1d8-4a605f4e62f1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do infuzji",
  "source": "urpl",
  "strength": "-",
  "packaging": "05909991203634 ¦ Rp ¦ 106032\n6 butelek 1000 ml\n05909991203641 ¦ Rp ¦ 106033\n10 butelek 250 ml\n05909991203658 ¦ Rp ¦ 106034\n10 butelek 500 ml",
  "substance": "Leucinum 8.9 mg/ml + Lysini acetas 5.74 mg/ml + Lisinum monohydricum 3.12 mg/ml + Methioninum 4.4 mg/ml + Phenylalaninum 4.7 mg/ml + Treoninum 4.2 mg/ml + Tryptophanum 1.6 mg/ml + Valinum 6.2 mg/ml + Arginina 11.5 mg/ml + Histidinum 3 mg/ml + Alaninum 10.5 mg/ml + Glicyna 12 mg/ml + Acidum asparaginicum 5.6 mg/ml + Glutamic acid 7 mg/ml + prolina 5.5 mg/ml + Serinum 2.3 mg/ml + Tyrosine 0.4 mg/ml + izoleucyna 5 mg/ml",
  "common_name": "Produkt złożony",
  "pl_product_id": "100250828",
  "pozwolenie_nr": "22232",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}

See everything about aminosäuren.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.